0001437402-26-000013
SEC filingArdelyx, Inc. reported total revenues of $407.3 million for fiscal year 2025, ending December 31, 2025. The company incurred a net loss of $61.6 million, which was driven by total costs and operating expenses of $448.3 million, including $337.2 million in selling, general and administrative expenses. The loss from operations was $41.0 million. The company's balance sheet shows total assets of $501.6 million, with current assets of $382.3 million including $68.0 million in cash and cash equivalents and $196.7 million in short-term investments. Total liabilities were $334.7 million, including long-term debt of $202.8 million, resulting in stockholders' equity of $166.9 million. Cash flow from operations was negative $42.5 million, while financing activities provided $54.5 million primarily from the 2022 Loan Agreement. The company ended the period with $96.1 million in cash and cash equivalents.
Ardelyx, Inc. reported total revenues of $407.3 million for fiscal year 2025 ending December 31, 2025. The company incurred a net loss of $61.6 million, which represents a significant financial result for the period. The loss from operations was $41.0 million, driven by total costs and operating expenses of $448.3 million. Key expense components included cost of sales at $39.5 million, research and development at $71.5 million, and selling, general and administrative expenses at $337.2 million. Interest expense contributed $20.1 million to the loss, while other income provided $8.7 million in offsetting benefit. The comprehensive loss was $61.5 million, slightly lower than the net loss due to $141,000 in unrealized gains on available-for-sale securities.
The company reported total revenues of $407.3 million for the fiscal year. No segment breakdown, geographic mix, or specific growth drivers were provided in the available data. The revenue figure represents the total income generated from all sources during the period. No comparative prior period revenue figures were provided in the data, preventing year-over-year growth analysis. The revenue composition was not detailed in terms of product sales, licensing, or other revenue streams in the provided information.
The company's financial results show significant operating losses with a loss from operations of $41.0 million on revenues of $407.3 million. Cost structure analysis reveals that selling, general and administrative expenses represented the largest component at $337.2 million, followed by research and development at $71.5 million, and cost of sales at $39.5 million. The net loss margin (net loss as percentage of revenue) was approximately 15.1%. No gross profit or gross margin figures were provided in the data, preventing detailed margin analysis. Operating margin was negative due to the operating loss position.
The company generated negative $42.5 million in cash from operating activities for the fiscal year. Investing activities used $9.0 million primarily from net investment purchases, while financing activities provided $54.5 million mainly from the 2022 Loan Agreement. The net increase in cash and cash equivalents was $3.1 million, ending the period with $96.1 million. The balance sheet shows total assets of $501.6 million, with current assets of $382.3 million including $68.0 million in cash and cash equivalents and $196.7 million in short-term investments. Total liabilities were $334.7 million, including long-term debt of $202.8 million, resulting in stockholders' equity of $166.9 million. The company's liquidity position appears supported by substantial current assets relative to current liabilities of $88.6 million.
No management guidance, strategic priorities, or specific risk factors were provided in the available data. The filing does not include forward-looking statements or outlook information in the provided content. Investors should refer to the complete 10-K filing for comprehensive risk factor disclosure and management discussion of future prospects. The available data focuses exclusively on historical financial results for the fiscal year ended December 31, 2025, without projection or guidance elements.